A 62-year-old woman comes to the clinic reporting intermittent vaginal spotting for the past month. She went through menopause at age 50. Her medical history is notable for estrogen receptor-positive breast cancer diagnosed three years ago, which was treated with lumpectomy, radiation therapy, and ongoing tamoxifen therapy. Vital signs are within normal limits. Pelvic examination demonstrates a normal-appearing vulva, thin vaginal mucosa, and a small amount of dark red blood in the vaginal vault. The cervix has no visible lesions. A transvaginal ultrasound reveals a heterogeneous endometrial stripe of 14 mm. Which of the following is the most appropriate next step in management?
- Endometrial biopsyCevap
- BDiscontinuation of tamoxifen and repeat ultrasonography
- CCervical cytology with human papillomavirus co-testing
- DMeasurement of serum CA-125 level
- EReassurance and routine annual follow-up
Cevap
Endometrial biopsy
The correct response is an endometrial biopsy. This patient presents with postmenopausal bleeding and a significantly thickened endometrial stripe (14 mm) on transvaginal ultrasound. Postmenopausal bleeding is the cardinal symptom of endometrial cancer. Her risk is substantially elevated due to her use of tamoxifen, a selective estrogen receptor modulator (SERM) that exerts anti-estrogenic effects on breast tissue but pro-estrogenic effects on the endometrium. Current guidelines mandate that any postmenopausal woman with vaginal bleeding and an endometrial thickness >4 mm undergo direct histologic evaluation via an endometrial biopsy to rule out endometrial hyperplasia or carcinoma.
Adım Adım Çözüm
Anahtar Kavram
Tamoxifen acts as an estrogen agonist on the endometrium, increasing the risk of endometrial cancer; therefore, postmenopausal bleeding in these patients requires prompt endometrial biopsy.